Géraldine E. Merle

Dr. Géraldine E. Merle

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2015 in Acta Biomaterialia
Verified
Journal Article
Closed access
ZSZeeshan Sheikh
Zeeshan Sheikh
YZYu Ling Zhang
Yu Ling Zhang
LGLiam Grover
Liam Grover
GMGéraldine E. Merle
Géraldine E. Merle
FTFaleh Mariño Tamimi
Faleh Mariño Tamimi
Jake BarraletJake Barralet
Jake Barralet

1 October 2019 in Nano Futures
Verified
Journal Article
Closed access
PDF file
ZZZishuai Zhang
Zishuai Zhang
AFAlison Fraser
Alison Fraser
SYSiyu Ye
Siyu Ye
GMGéraldine E. Merle
Géraldine E. Merle
Jake BarraletJake Barralet
Jake Barralet
With its unique physical properties, graphene creates an exceptional platform for fundamental science and a promising material for many applications. However, the large-scale production of graphene with high quality and few layers is still challenging. To understanding the preparation methods of the graphene and the influence of their process parameters on the electronic structure is not only crucial for developing its applications in research fields, but also vital for the future graphene industrial production. This work is an overview of the most state-of-the-art research approaches and latest advancement described in the literature for synthesizing graphene and their associated properties.

1 September 2020 in Bone
Verified
Journal Article
Closed access
DSDrew Schupbach
Drew Schupbach
MCMarianne Comeau-Gauthier
Marianne Comeau-Gauthier
EHEdward Harvey
Edward Harvey
GMGéraldine E. Merle
Géraldine E. Merle

10 May 2020 in Biotechnology Journal
Verified
Journal Article
Closed access
PDF file
FMFrancis McEachern
Francis McEachern
EHEdward Harvey
Edward Harvey
GMGéraldine E. Merle
Géraldine E. Merle

16 June 2025 in Biomolecules
Verified
Journal Article
Open access
PDF file
MAMuskan Alad
Muskan Alad
FYFajer Yousef
Fajer Yousef
Laura M EpureLaura M Epure
Laura M Epure
ALAngelina Young-In Lui
Angelina Young-In Lui
MGMichael Grant
Michael Grant
FMFackson Mwale
Fackson Mwale
Osteoarthritis (OA) is now widely recognized not merely as a cartilage-centric disease but as a multifactorial disorder affecting the entire joint as an organ, including the articular cartilage, subchondral bone, synovium, ligaments, menisci, and the innervating neural elements. This review explores the complex pathophysiology of OA with a focus on the emerging mechanisms of pain and inflammation that extend beyond articular cartilage degradation. Joint inflammation driven by immune activation in response to cellular stress signals promotes the release of pro-inflammatory mediators and catabolic enzymes. Key signaling pathways such as NF-κB, MAPKs, and JAK/STAT amplify these responses, and pain is sustained through peripheral and central sensitization, contributing to exacerbating symptoms even in the absence of visible joint damage. This review also integrates molecular and cellular mechanisms to highlight innovative therapies aimed at modifying both the structural damage and neurosensory drivers of pain. These approaches offer the potential to not only alleviate symptoms but also alter disease progression, signaling a move toward personalized, mechanism-based treatments. Given the intricate interactions among joint tissues, immune activation, and sensory processing, a comprehensive strategy that targets both structural degeneration and neuroinflammation is essential for the future of OA management. Emphasizing the joint as an integrated organ, we advocate for translational research linking molecular pathology with clinically meaningful outcomes.

17 January 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
DVDaniela Vieira
Daniela Vieira
SASamuel N. Angel
Samuel N. Angel
YHYazan Honjol
Yazan Honjol
MMMaude Masse
Maude Masse
SGSamantha Gruenheid
Samantha Gruenheid
GMGéraldine E. Merle
Géraldine E. Merle
Surgical site infections (SSIs) account for a massive economic, physiological, and psychological burden on patients and health care providers. Sutures provide a surface to which bacteria can adhere, proliferate, and promote SSIs. Current methods for fighting SSIs involve the use of sutures coated with common antibiotics (triclosan). Unfortunately, these antibiotics have been rendered ineffective due to the increasing rate of antibiotic resistance. A promising new avenue involves the use of metallic nanoparticles (MNPs). MNPs exhibit low cytotoxicity and a strong propensity for killing bacteria while evading the typical antibiotic resistance mechanisms. In this work, we developed a novel MNPs dip-coating method for PDS-II sutures and explored the capabilities of a variety of MNPs in killing bacteria while retaining the cytocompatibility. Our findings indicated that our technique provided a homogeneous coating for PDS-II sutures, maintaining the strength, structural integrity, and degradability. The MNP coatings possess strong in vitro antibacterial properties against P aeruginosa and S. aureus—varying the %of dead bacteria from ~ 40% (for MgO NPs) to ~ 90% (for Fe2O3) compared to ~ 15% for uncoated PDS-II suture, after 7 days. All sutures demonstrated minimal cytotoxicity (cell viability > 70%) reinforcing the movement towards the use MNPs as a viable antibacterial technology.